Conal Hayton

1.3k total citations · 1 hit paper
22 papers, 889 citations indexed

About

Conal Hayton is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Biomedical Engineering. According to data from OpenAlex, Conal Hayton has authored 22 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 6 papers in Physiology and 5 papers in Biomedical Engineering. Recurrent topics in Conal Hayton's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (15 papers), Sarcoidosis and Beryllium Toxicity Research (6 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers). Conal Hayton is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (15 papers), Sarcoidosis and Beryllium Toxicity Research (6 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers). Conal Hayton collaborates with scholars based in United Kingdom, Italy and Slovenia. Conal Hayton's co-authors include Nazia Chaudhuri, Shaney Barratt, Andrew Creamer, C.T. Leonard, Andrew M. Wilson, Emma Coombes, Allan Clark, Andy Jones, Kim Linton and Nicholas Weatherley and has published in prestigious journals such as Thorax, Lung Cancer and Respiratory Medicine.

In The Last Decade

Conal Hayton

20 papers receiving 874 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Idiopathic Pulmonary Fibrosis (IPF): An Overview

2018 267 citations Shaney Barratt, Andrew Creamer et al. Journal of Clinical Medicine profile →

Peers

Countries citing papers authored by Conal Hayton

Since Specialization

Citations

This map shows the geographic impact of Conal Hayton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Conal Hayton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Conal Hayton more than expected).

Fields of papers citing papers by Conal Hayton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Conal Hayton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Conal Hayton. The network helps show where Conal Hayton may publish in the future.

Co-authorship network of co-authors of Conal Hayton

This figure shows the co-authorship network connecting the top 25 collaborators of Conal Hayton. A scholar is included among the top collaborators of Conal Hayton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Conal Hayton. Conal Hayton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: Adverse events and survival from a UK tertiary centre 2025 ·Lung Cancer ·(unknown), Conal Hayton, Ashutosh Lodhi, (unknown), Corinne Faivre‐Finn	0
2	Relationship between exhaled volatile organic compounds and lung function change in idiopathic pulmonary fibrosis 2025 ·Thorax ·Conal Hayton, Waqar Ahmed, (unknown), Iain R. White, Nazia Chaudhuri, (unknown), Andrew M. Wilson, Stephen J. Fowler	0
3	Changes in lung epithelial cell volatile metabolite profile induced by pro-fibrotic stimulation with TGF-β1 2023 ·Journal of Breath Research ·Conal Hayton, Waqar Ahmed, Peter S. Cunningham, Karen Piper Hanley, (unknown), Nazia Chaudhuri, C.T. Leonard, John Blaikley, Stephen J. Fowler	2
4	The detection, assessment and clinical evolution of interstitial lung abnormalities identified through lung cancer screening 2023 ·ERJ Open Research ·Haval Balata, (unknown), Nazia Chaudhuri, Melanie Greaves, Janelle Yorke, Richard Booton, Philip Crosbie, Conal Hayton	9
5	Exhaled volatile organic compounds in idiopathic pulmonary fibrosis and disease progression 2020 ·Conal Hayton, (unknown), Waqar Ahmed, Iain R. White, (unknown), (unknown), Nazia Chaudhuri, Andrew Wilson, C.T. Leonard, (unknown)	1
6	Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review 2019 ·Respiratory Research ·Conal Hayton, (unknown), Andrew M. Wilson, Nazia Chaudhuri, C.T. Leonard, Stephen J. Fowler	25
7	Transbronchial Lung Cryobiopsy in Idiopathic Pulmonary Fibrosis: A State of the Art Review 2019 ·Advances in Therapy ·(unknown), Gareth Hughes, Stefan Stanel, Nazia Chaudhuri, Conal Hayton	7
8	The role of measuring exhaled breath biomarkers in sarcoidosis: a systematic review 2019 ·Journal of Breath Research ·(unknown), Conal Hayton, (unknown), Stephen J. Fowler, William D. Fraser, Andrew M. Wilson	14
9	Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience 2018 ·Therapeutic Advances in Respiratory Disease ·Pilar Rivera‐Ortega, Conal Hayton, John Blaikley, C.T. Leonard, Nazia Chaudhuri	65
10	Drug induced interstitial lung disease: a systematic review 2018 ·Sarah Skeoch, Nicholas Weatherley, Andrew J. Swift, Alexander Oldroyd, Christopher Johns, Conal Hayton, (unknown), Jim M. Wild, John C. Waterton, Maya H Buch, Kim Linton, Ian N Bruce, C.T. Leonard, (unknown), Nazia Chaudhuri	21
11	What can we learn from Idiopathic Pulmonary Fibrosis Registries? 2018 ·(unknown), C.T. Leonard, Pilar Rivera‐Ortega, Helen Morris, Tracey Marshall, (unknown), (unknown), Conal Hayton, Melanie Greaves, John Blaikley, Nazia Chaudhuri	1
12	Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think? 2018 ·Helen Morris, Tracey Marshall, (unknown), (unknown), Conal Hayton, Pilar Rivera‐Ortega, (unknown), John Blaikley, Nazia Chaudhuri	1
13	Breath Biomarkers in Idiopathic Pulmonary Fibrosis: A Systematic Review 2018 ·Conal Hayton, (unknown), Andrew M. Wilson, Nazia Chaudhuri, C.T. Leonard, Stephen J. Fowler	1
14	Drug-Induced Interstitial Lung Disease: A Systematic Review 2018 ·Journal of Clinical Medicine ·Sarah Skeoch, Nicholas Weatherley, Andrew J. Swift, Alexander Oldroyd, Christopher Johns, Conal Hayton, Alessandro Giollo, Jim M. Wild, John C. Waterton, Maya H Buch, Kim Linton, Ian N Bruce, C.T. Leonard, Stephen Bianchi, Nazia Chaudhuri	236
15	Idiopathic Pulmonary Fibrosis (IPF): An Overview breakdown → 2018 ·Journal of Clinical Medicine ·Shaney Barratt, Andrew Creamer, Conal Hayton, Nazia Chaudhuri	267
16	Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age 2017 ·Journal of Thoracic Disease ·(unknown), Tracey Marshall, Helen Morris, Conal Hayton, Nazia Chaudhuri	18
17	Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient? 2017 ·Drugs & Aging ·Conal Hayton, Nazia Chaudhuri	9
18	Current Treatments in the Management of Idiopathic Pulmonary Fibrosis: Pirfenidone and Nintedanib 2017 ·Research Explorer (The University of Manchester) ·Conal Hayton, Nazia Chaudhuri	7
19	Nintedanib for treating idiopathic pulmonary fibrosis 2016 ·British Journal of Healthcare Management ·Conal Hayton, Nazia Chaudhuri	11
20	Barriers to pulmonary rehabilitation: Characteristics that predict patient attendance and adherence 2012 ·Respiratory Medicine ·Conal Hayton, Allan Clark, (unknown), (unknown), (unknown), (unknown), (unknown), Andy Jones, Emma Coombes, Andrew M. Wilson	191

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact